« Return to archives | Awards & Advancement

VisionCare closes financing, makes board changes

Tuesday, January 24, 2012 12:51 PM

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, will close a Series E financing with Agate Medical Investments leading the expansion round.  Agate's managing general partner, Chanan Schneider, will join the VisionCare team as a board observer.

Allen W. Hill, VisionCare's CEO, said the financing will accelerate the commercial launch of its telescope implant for treating end-stage macular degeneration.

Schneider, managing general partner of Agate, previously was CEO of Beta-O2, a bio-device company, and managing director at Discount Capital Markets, where he led medtech and other technology investments.  

VisionCare also has added two new members to its board of directors: David Israeli, M.D., Pitango Venture Capital, and Yuval Avni, M.D., Giza Venture Capital.

Israeli joined Pitango in 2010 as a venture partner in the life sciences team, focusing on the medical device and biopharmaceuticals sectors. Previously, Israeli held positions at Medtronic and Rythmia Medical.

Avni is a partner at Giza Venture Capital, focusing on investments in life science and cleantech sectors. He is a medical practitioner with clinical experience in general and vascular surgery, and conducted clinical research in human genetics prior to entering the venture capital field.

Share:          
CWWeekly

February 21

Survey: Sponsors, CROs making changes to their business models to demonstrate value to payers

Cegedim ranks top pharma companies on their use of, and success with, social media

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

February

Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have...

Closing investigative site operations a complex process
In light of the shrinking investigative site landscape, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into...

Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company, directly marketing its products in over 50 countries...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.